Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Late filing: transactions July 9–13 at $17.19/$16.71/$17.24 per tranche. Via HH Talent Limited (CEO personal vehicle) under 10b5-1 plan adopted Dec 25, 2025. Current price $16.50 (-3.6% from avg buy of ~$17.12). Active accumulation campaign.
Jul 16: 116,671 shares @ $3.56 avg; Jul 17: 50,945 shares @ $3.52 avg. Indirect via Tang Capital Partners LP & affiliates. Post-purchase total: 7,080,945 shares. Prior tranche ~$891K filed Jul 15. Current price $3.62 (+2.3% from avg buy ~$3.54).
AIThe day in insider buying
SEC Form 4 Insider Scan — July 21, 2026
Scanned the last 24 hours of EDGAR Form 4 filings. 2 qualifying buys (≥ $250K, transaction type P) totalling $9.1M.
Headline Filings
COE — Jack Jiajia Huang (CEO) bought 495,360 shares ≈ $8.48M at ~$17.12 avg (via HH Talent Limited, 10b5-1); now $16.50 (-3.6% since buy). (filing)
FULC — Kevin Tang (10% Owner / Tang Capital) bought 167,616 shares ≈ $594K at ~$3.54 avg; now $3.62 (+2.3% since buy). (filing)
Notes
COE (51Talk/China Online Education Group): Late filing — transactions occurred July 9–13 but Form 4 filed July 20. CEO purchased under a Rule 10b5-1 plan adopted December 25, 2025 via personal vehicle HH Talent Limited. Stock currently underwater vs. the buy price by ~3.6%.
FULC (Fulcrum Therapeutics): Kevin Tang continues to accumulate at $3.52–$3.56 range, adding to an existing 7M+ share position. Tang Capital is a known concentrated biotech investor; this is part of a multi-week accumulation campaign (prior tranche ~$891K filed July 15). Stock is slightly in the green vs. the buy price.
Notable exclusions: CBIO (Crescent Biopharma) — P-coded $20M was participation in company's $143.7M public offering, not secondary-market buy. LNBIX (Lincoln Financial/Lincoln Bain) — $25M was investment adviser adding to managed trust, not traditional insider.
Most-bought stocks, last 30 days
AVO$74.5M · 14 buys, 4 insidersMission Produce, Inc.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.